The study tracks the long-term kinetics of antibody responses to SARS-CoV-2 after vaccination and infections in New York healthcare workers from 2020 to 2023. It reveals that antibody waning is slower after booster shots, but there's an upper limit to antibody levels, which gradually lowers with repeated SARS-CoV-2 exposures and vaccinations.
By Neha MathurAug 31 2023Reviewed by Benedette Cuffari, M.Sc. In a recent article posted to the medRxiv preprint* server, researchers assess the longevity of severe acute respiratory syndrome coronavirus 2 humoral immune responses and their kinetics after initial infection and coronavirus disease 2019 vaccination. Additionally, they determined SARS-CoV-2 re-infection rates and assessed correlates of protection against SARS-CoV-2 infection.
Short-term studies evaluating limited data points following peak immune responses to SARS-CoV-2 infection showed that messenger ribonucleic acid technology-based COVID-19 vaccines induced immunity waned quickly. Furthermore, the emergence of new SARS-CoV-2 variants decreased the effectiveness of these vaccines against symptomatic disease.
Related StoriesThe interval between study visits was two to four weeks from initiation to week eight. After that, this interval increased to four to eight weeks after week eight. After primary vaccination, plasmablast-derived serum antibodies reached a high peak immediately; however, this antibody response began to wane within two weeks. These antibodies constituted the 28-34-day half-life of the short-lived component of the PARIS model; however, some antibodies, like immunoglobulin G1 , had a half-life of around four weeks.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study helps explain SARS-CoV-2 variants' rapid spreadThe omicron variants of the SARS-CoV-2 virus, which have rapidly spread around the world over the past year, latch onto our cells more tightly, invade them more efficiently, and elude many of the antibodies induced by previous infections and vaccines. These are some of the key findings from a multinational team of researchers reporting today in the journal Nature.
Read more »
How frequent are hospital-onset SARS-CoV-2 infections and what hospital characteristics are associated with rates of hospital-onset SARS-CoV-2 infections?Researchers investigated the frequency of hospital-onset COVID-19 cases and the hospital characteristics related to hospital-onset infections by SARS-CoV-2 in US.
Read more »
Growing concerns about newly emerging 'Pirola' BA.2.86, a SARS-CoV-2 subvariantScientists around the world are growing more concerned about a newly emerging subvariant of the SARS-CoV-2 virus—named BA.2.86 and referred to generically as 'Pirola'—according to Mun-Keat Loo, international features editor for the medical journal BMJ.
Read more »
Inhaled receptor decoy therapy confers protection against SARS-CoV-2 infection in preclinical modelsThe surface protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as the spike protein, is critical for infecting host cells. The spike protein facilitates the infection process by binding to angiotensin-converting enzyme 2 (ACE2) receptors on the surface of airway epithelial cells, initiating the virus entry into the cells.
Read more »
Nearly half of phones tested during pandemic carried COVID-19 virus, finds systematic reviewAlmost half of mobile phones tested at the height of the pandemic were contaminated with the SARS-CoV-2 virus, bolstering a theory that the devices supercharged the spread of COVID-19.
Read more »
Study demonstrates adding complex component of milk to infant formula confers long-term cognitive benefitsBreast milk is widely acknowledged as the most beneficial nutrition for infants, but many families face medical or logistical challenges in breastfeeding. In the U.S., just 45% of infants continue to be exclusively breastfed at 3 months of age, according to the Centers for Disease Control.
Read more »